K
Kenneth A. Newlander
Researcher at GlaxoSmithKline
Publications - 65
Citations - 2642
Kenneth A. Newlander is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Transplantation & Cancer. The author has an hindex of 25, co-authored 65 publications receiving 2536 citations.
Papers
More filters
Journal ArticleDOI
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K. Verma,Xinrong Tian,Louis V. LaFrance,Celine Duquenne,Dominic Suarez,Kenneth A. Newlander,Stuart Paul Romeril,Joelle Lorraine Burgess,Seth W. Grant,Brackley James,Alan P. Graves,Daryl A. Scherzer,Art Shu,Christine Thompson,Heidi M. Ott,Glenn S. Van Aller,Carl A. Machutta,Elsie Diaz,Yong Jiang,Johnson Neil W,Steven D. Knight,Ryan G. Kruger,Michael T. McCabe,Dashyant Dhanak,Peter J. Tummino,Caretha L. Creasy,William H. Miller +26 more
TL;DR: This work has identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 and GSK343, which are small molecule chemical tools that would be useful to further explore the biology of EZh2.
Patent
Compounds, compositions, and methods
Andrew Mcdonald,Gustave Bergnes,Bainian Feng,David J. Morgans,Steven David Knight,Kenneth A. Newlander,Dashyant Dhanak,Brook Christopher S +7 more
TL;DR: In this article, compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed. But none of these compounds are suitable for treating cancer.
Journal ArticleDOI
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
David J. Payne,William H. Miller,Valerie Berry,John Brosky,Walter J. Burgess,Emile Chen,Walter E. DeWolf,Andrew P. Fosberry,Rebecca Claire Greenwood,Martha S. Head,Dirk A. Heerding,Cheryl A. Janson,Deborah Dee Jaworski,Paul M. Keller,Manley Peter J,Terrance D. Moore,Kenneth A. Newlander,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Courtney Slater-Radosti,Kevin L. Salyers,Mark A. Seefeld,Martin G. Smyth,Dennis T. Takata,Irene N. Uzinskas,Kalindi Vaidya,Nicola G. Wallis,Scott B. Winram,Catherine C.K. Yuan,William F. Huffman +31 more
TL;DR: Results show that compound 4 is representative of a new, totally synthetic series of antibacterial agents that has the potential to provide novel alternatives for the treatment of S. aureus infections that are resistant to the present armory of antibiotics.
Journal ArticleDOI
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Mark A. Seefeld,William H. Miller,Kenneth A. Newlander,Walter J. Burgess,Walter E. DeWolf,Patricia A. Elkins,Martha S. Head,Dalia R. Jakas,Cheryl A. Janson,Paul M. Keller,Manley Peter J,Terrance D. Moore,David J. Payne,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Irene N. Uzinskas,Nicola G. Wallis,William F. Huffman +19 more
TL;DR: The hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents is supported, with a new series of inhibitors developed with greatly increased potency against FabI-containing organisms.
Patent
Bicyclic fibrinogen antagonists
Bondinell William E,James F. Callahan,William F. Huffman,Richard M. Keenan,Thomas W. Ku,Kenneth A. Newlander +5 more
TL;DR: In this paper, the authors proposed a method for inhibiting platelet aggregation in compounds of formula (I), where A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N, and D1 to D4 may be optionally oxidized.